In­ter­view­ing the ex­hibitors

Com­pany top man­age­ment talk about plans for up­com­ing CIIE im­port expo

Global Times – Metro Shanghai - - CITY PANORAMA -

Ed­i­tors’ Note:

The first China In­ter­na­tional Im­port Expo (CIIE) will be held from Novem­ber 5 to 10 in Shang­hai, and more than 3,000 en­ter­prises from over 130 coun­tries and re­gions will dis­play and sell their prod­ucts and ser­vices. Th­ese ex­hibitors re­gard this event as a big plat­form for them to com­mu­ni­cate with the pub­lic, the me­dia and ex­perts from var­i­ous in­dus­tries. The Global Times re­cently in­ter­viewed a num­ber of ex­ec­u­tives from some of the ex­hibitors at­tend­ing the up­com­ing CIIE. They will in­tro­duce how they are pre­par­ing for the forth­com­ing event, their ex­pec­ta­tions of the expo and their fu­ture plans in the Chi­nese mar­ket. Our in­ter­vie­wees to­day are Vladimir Makat­saria, chair­man of John­son & John­son China and Leon Wang, ex­ec­u­tive vice pres­i­dent, in­ter­na­tional and China pres­i­dent of As­traZeneca.

GT: How will you par­tic­i­pate in CIIE? Is there any­thing new or in­ter­est­ing you’d like to show and share dur­ing the expo?

Makat­saria: As the world’s largest health­care com­pany, we are very pleased to in­tro­duce our in­dus­try-lead­ing in­no­va­tive prod­ucts at CIIE. We are bring­ing a wealth of cut­ting-edge tech­nol­ogy and, for the first time in China, de­but­ing our CARTO 3-D catheter po­si­tion­ing tech­nol­ogy to help elec­tro­phys­i­ol­o­gists op­ti­mize care and Lip­iFlow Ther­mal Pul­sa­tion Sys­tem for the treat­ment of mei­bo­mian gland dys­func­tion. We are fo­cus­ing on the most press­ing health­care needs through med­i­cal de­vices and phar­ma­ceu­ti­cals, and bring­ing prod­ucts which cover a range of con­di­tions in­clud­ing chronic lym­pho­cytic leukemia, lym­phoma, mul­ti­ple myeloma, rheuma­toid arthri­tis and hu­man im­mun­od­e­fi­ciency virus (HIV), as well as surgery, spinal medicine, elec­tro­phys­i­ol­ogy and trauma. We will have an in­ter­ac­tive area where vis­i­tors can ex­pe­ri­ence vis­ual health tests in per­son to learn more about eye care and eye health.

GT: This year marks the 40th an­niver­sary of China’s re­form and open­ing-up. When was the first time that your prod­uct en­tered the Chi­nese mar­ket?

Makat­saria: Since found­ing our first joint ven­ture – Xi’an Janssen – in 1985, we have been a leader in China’s health­care in­dus­try. Our first prod­ucts – Si­belium, Motil­ium and Dak­tarin – en­tered the China mar­ket in 1989 and are now all house­hold names. From then on, we have been com­mit­ted to bring­ing health­care so­lu­tions to ad­dress the sig­nif­i­cant un­met needs of mil­lions of Chi­nese pa­tients and con­sumers. The changes in China have been pro­found. We now feel that China is poised to trans­form health­care glob­ally, as a con­flu­ence of fac­tors – in­vest­ment, AI, cloud com­put­ing, big data and far­sighted gov­ern­ment poli­cies – cre­at­ing an en­vi­ron­ment where in­no­va­tion will im­prove health out­comes and qual­ity of life.

GT: What do you think of China’s first-ever In­ter­na­tional Im­port Expo? Do you have any ex­pec­ta­tions for this event? What goals do you hope to achieve through it?

Makat­saria: We see CIIE as an ideal plat­form to carry out more in-depth ex­changes with gov­ern­ments, en­ter­prises and other stake­hold­ers and jointly dis­cuss the de­vel­op­ment of the health­care in­dus­try. We are very pleased to be able to in­tro­duce our world-lead­ing diver­si­fied lineup of in­no­va­tive prod­ucts and tech­nolo­gies to China and are one of the big­gest health­care ex­hibitors at this year’s CIIE. We hope to in­tro­duce our more than 30 years of de­vel­op­ment in China, and that we can strengthen ex­change and co­op­er­a­tion with a wide range of Chi­nese health­care ac­tors.

GT: How im­por­tant is the Chi­nese mar­ket and its con­sumers to your com­pany and your prod­uct?

Makat­saria: China is a key mar­ket in our world­wide busi­ness. As the coun­try tran­si­tions to­ward a new era, we are strength­en­ing our part­ner­ship with China by con­tin­u­ing to lay down strong roots through on­go­ing in­vest­ment in our in­no­va­tion and man­u­fac­tur­ing fa­cil­i­ties to fur­ther im­prove the health of the Chi­nese pub­lic. J&J is con­fi­dent in China’s po­ten­tial and its de­vel­op­ment into a key global in­no­va­tion hub. In 2017, we be­gan the con­struc­tion of our $180-mil­lion new Ethicon fac­tory in Suzhou, which will pro­duce high qual­ity sur­gi­cal prod­ucts to more ef­fec­tively treat a broad range of crit­i­cal dis­eases such as lung can­cer, liver can­cer and stom­ach can­cer.

GT: How will you par­tic­i­pate in CIIE? Is there any­thing new or in­ter­est­ing you’d like to show and share dur­ing the expo?

Wang: With its China head­quar­ters in Shang­hai, As­traZeneca has pre­pared for CIIE for nearly six months. Dur­ing the expo, we will fo­cus on five ther­apy ar­eas where Chi­nese pa­tients have the most ur­gent need: res­pi­ra­tory, car­dio­vas­cu­lar, meta­bolic, on­col­ogy and gas­troin­testi­nal dis­eases, and dis­play 30 in­no­va­tive drugs we have in­tro­duced into China over the past 25 years. Th­ese drugs in­clude Ta­grisso for lung can­cer treat­ment, Forx­iga for di­a­betes treat­ment and Lyn­paraza, the first gene-tar­geted drug for ovar­ian can­cer that was li­censed by the Chi­nese gov­ern­ment in Au­gust.

We also plan to show­case As­traZeneca’s lead­ing di­ag­no­sis-and-treat­ment-in­te­grated holis­tic dis­ease man­age­ment so­lu­tions, such as China Chest Pain Cen­ter, Na­tional Meta­bolic Man­age­ment Cen­ter and In­te­grated Lung Can­cer Cen­ter, be­ing cre­ated with the help of the In­ter­net of Things, ar­ti­fi­cial in­tel­li­gence, big data and other cut­ting-edge tech­nolo­gies in the fields of res­pi­ra­tory, car­dio­vas­cu­lar, meta­bolic and gas­troin­testi­nal and on­col­ogy. They al­low view­ers to per­son­ally ex­pe­ri­ence the power brought by smart tech­nol­ogy into hu­man health.

GT: This year marks the 40th an­niver­sary of China’s re­form and open­ing-up. When was the first time that your prod­uct en­tered the Chi­nese mar­ket?

Wang: As­traZeneca has been in China for 25 years. Over the past 25 years, we have wit­nessed this coun­try trans­form from an ex­port-ori­ented econ­omy to a very open econ­omy. As­traZeneca is not only the con­trib­u­tor but also a ben­e­fi­ciary of China’s re­form and open­ing-up. To­day, through ex­pand­ing do­mes­tic de­mand and boost­ing con­sump­tion, China em­braces prod­ucts and en­ter­prises from the whole world. With the bonus of its own eco­nomic growth, China also helps to up­grade in­dus­tries and to pro­mote global eco­nomic de­vel­op­ment.

GT: What do you think of China’s first-ever In­ter­na­tional Im­port Expo? Do you have any ex­pec­ta­tions for this event? What goals do you hope to achieve through it?

Wang: As a Chi­nese and Shang­hainese cit­i­zen my­self, I think CIIE is ex­cit­ing and mean­ing­ful, show­ing that China’s re­form and open­ing-up is com­ing to a new stage. It brings global prod­ucts into China and con­trib­utes in the do­mes­tic con­sump­tion up­grad­ing.

The expo ac­cords with the build­ing of a com­mu­nity with shared fu­ture for mankind that Pres­i­dent Xi Jin­ping pro­posed, and lets the global econ­omy ben­e­fit from China.

By par­tic­i­pat­ing in CIIE, As­traZeneca will fur­ther demon­strate its pos­i­tive and open co-op­er­a­tional at­ti­tude and join hands with more in­dus­try-lead­ing cross-sec­tor part­ners in the fu­ture to jointly im­prove the ac­ces­si­bil­ity and ef­fi­ciency of China’s health ser­vices, so as to con­trib­ute to re­al­iz­ing the goal of the gov­ern­ment’s “Health China 2030” plan.

GT: How im­por­tant is the Chi­nese mar­ket and its con­sumers to your com­pany and your prod­uct?

Wang: Since en­ter­ing China in 1993, As­traZeneca has in­vested over $1 bil­lion in the re­search and de­vel­op­ment of lifechang­ing medicines in this coun­try. We are China’s sec­ond largest multi­na­tional phar­ma­ceu­ti­cal com­pany.

Over the past 25 years, China has de­vel­oped into the world’s sec­ond­largest mar­ket for As­traZeneca. China is pro­gres­sively show­cas­ing its im­por­tant strate­gic po­si­tion in As­traZeneca’s global map in re­search and de­vel­op­ment, op­er­a­tion and com­mer­cial in­no­va­tion. As­traZeneca ac­tively pro­motes the re­search and de­vel­op­ment of in­no­va­tive drugs in China, cov­er­ing on­col­ogy, res­pi­ra­tory and re­nal dis­eases and other fields. We will con­tinue ac­cel­er­at­ing the list­ing of in­no­va­tive drugs into Chi­nese mar­kets as well.

Vladimir Makat­saria, chair­man of John­son & John­son China

Leon Wang, ex­ec­u­tive vice pres­i­dent, in­ter­na­tional and China pres­i­dent of As­traZeneca

Newspapers in English

Newspapers from China

© PressReader. All rights reserved.